Scientists map genetic secrets of blood cancers to find new treatments
NCT ID NCT07445984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects and analyzes genetic and molecular data from 250 people with various blood cancers, including leukemia and lymphoma. Researchers will test cancer cells in the lab with many drugs to see which ones work best. The goal is to match genetic features with drug responses, paving the way for more personalized cancer treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify new drug targets and personalized treatment options for people with blood cancers.
- What could go wrong
- This is an early-stage, observational study that does not test a specific treatment. Results may not directly lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Parma
RECRUITINGParma, PR, 43126, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a smart tool keep watch on leukemia after treatment stops?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Could bone marrow from deceased donors cure blood cancers?
- New dashboard aims to make leukemia trials more inclusive
- Gene mapping of childhood blood cancers could unlock personalized treatments